176 related articles for article (PubMed ID: 32519171)
21. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Chen RW; Li H; Bernstein SH; Kahwash S; Rimsza LM; Forman SJ; Constine L; Shea TC; Cashen AF; Blum KA; Fenske TS; Barr PM; Phillips T; Leblanc M; Fisher RI; Cheson BD; Smith SM; Faham M; Wilkins J; Leonard JP; Kahl BS; Friedberg JW
Br J Haematol; 2017 Mar; 176(5):759-769. PubMed ID: 27992063
[TBL] [Abstract][Full Text] [Related]
22. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
23. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
Martin P; Chadburn A; Christos P; Furman R; Ruan J; Joyce MA; Fusco E; Glynn P; Elstrom R; Niesvizky R; Feldman EJ; Shore TB; Schuster MW; Ely S; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
Ann Oncol; 2008 Jul; 19(7):1327-1330. PubMed ID: 18349031
[TBL] [Abstract][Full Text] [Related]
24. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
[TBL] [Abstract][Full Text] [Related]
25. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
26. Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report.
Jo JC; Kim SJ; Lee HS; Eom HS; Lee SI; Park Y; Lee JO; Lee Y; Yhim HY; Yang DH; Byun JM; Kang HJ; Kim HJ; Shin HJ; Yoo KH; Suh C;
Ann Hematol; 2020 Feb; 99(2):223-228. PubMed ID: 31853704
[TBL] [Abstract][Full Text] [Related]
27. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Kanaji N; Ishibashi K; Uno H; Hino N
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience.
Bhatt VR; Loberiza FR; Smith LM; Armitage JO; Greiner TC; Bast M; Lunning MA; Bierman PJ; Vose JM; Bociek RG
Leuk Lymphoma; 2016; 57(6):1327-34. PubMed ID: 26377137
[TBL] [Abstract][Full Text] [Related]
29. Mantle cell lymphoma: a Turkish Multi-Center Study.
Okay M; Meletli O; Kelkitli E; Malkan UY; Turgut M; Buyukasik Y; Tekin F; Demiroglu H; Goker H
J BUON; 2019; 24(5):2084-2089. PubMed ID: 31786879
[TBL] [Abstract][Full Text] [Related]
30. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP; Khoury HJ; Langston AA
Bone Marrow Transplant; 2008 Oct; 42(8):529-34. PubMed ID: 18622414
[TBL] [Abstract][Full Text] [Related]
31. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant.
Andersen NS; Pedersen L; Elonen E; Johnson A; Kolstad A; Franssila K; Langholm R; Ralfkiaer E; Akerman M; Eriksson M; Kuittinen O; Geisler CH;
Eur J Haematol; 2003 Aug; 71(2):73-80. PubMed ID: 12890145
[TBL] [Abstract][Full Text] [Related]
32. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
33. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
[TBL] [Abstract][Full Text] [Related]
34. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
Drach J; Huang H; Samoilova O; Belch A; Farber C; Bosly A; Novak J; Zaucha J; Dascalescu A; Bunworasate U; Masliak Z; Vilchevskaya K; Robak T; Pei L; Rooney B; van de Velde H; Cavalli F
Leuk Lymphoma; 2018 Apr; 59(4):896-903. PubMed ID: 29338540
[TBL] [Abstract][Full Text] [Related]
36. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang M; Cohen JB; Churnetski M; Hill BT; Sawalha Y; Hernandez-Ilizaliturri FJ; Kothari S; Vose JM; Bast M; Fenske T; Rao Gari SN; Maddocks KJ; Bond D; Bachanova V; Kolla B; Chavez J; Shah B; Lansigan F; Burns T; Donovan AM; Wagner-Johnston N; Messmer M; Mehta A; Anderson JK; Reddy N; Kovach AE; Landsburg DJ; Glenn M; Inwards DJ; Ristow K; Karmali R; Kaplan JB; Caimi PF; Rajguru S; Evens A; Klein A; Umyarova E; Pulluri B; Amengual JE; Lue JK; Diefenbach C; Fisher RI; Barta SK
Blood Adv; 2023 Dec; 7(24):7393-7401. PubMed ID: 37874912
[TBL] [Abstract][Full Text] [Related]
38. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?
Kedmi M; Avivi I; Ribakovsky E; Benyamini N; Davidson T; Goshen E; Tadmor T; Nagler A; Avigdor A
Leuk Lymphoma; 2014 Nov; 55(11):2484-9. PubMed ID: 24432895
[TBL] [Abstract][Full Text] [Related]
39. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.
Freedman AS; Neuberg D; Gribben JG; Mauch P; Soiffer RJ; Fisher DC; Anderson KC; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler LM
J Clin Oncol; 1998 Jan; 16(1):13-8. PubMed ID: 9440717
[TBL] [Abstract][Full Text] [Related]
40. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
